Regeneron's new take on bispecifics: activating complement

Why Regeneron built a bispecific platform that harnesses the complement system

Regeneron's new bispecific antibodies for the first time tap the complement system -- going beyond the immune cells traditionally targeted, and expanding the modality into new patient populations and indications.

With proof of concept studies against bacteria as well as cancer, the data advance the possibility that bispecifics could add to the sorely needed

Read the full 549 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers